How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

387 results for

Yasmin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Yaz / Yasmin: Safety Considerations related to VTE

Yaz / Yasmin: Safety Considerations related to VTE RxFiles: Q&A Summary www.RxFiles.ca - Jan. 2011 (Updated Dec. 2011) D. Bunka, BScPharm & J. Hall, BScPharm, PharmD Candidate YAZ / YASMIN: Safety Considerations related to Venous Thromboembolism (VTE) Bottom Line: The use of CHCs increases a woman's risk of VTE relative to non-users; however the estimated absolute risk for users of any type of CHC is very low and even lower than the risk during pregnancy and postpartum. Recent scientific focus (...) has been placed on estimating the risk of VTE associated with the use of drospirenone (DRSP), i.e. Yaz & Yasmin, relative to older progestins. Small, observed differences in VTE risk have been reported among different progestins, suggesting the estimated risk may be slightly higher with DRSP compared to levonorgestrel. Some experts feel it is prudent for most women to first consider a contraceptive containing levonorgestrel or norethindrone, with as low a dose of estrogen as possible, given

2011 RxFiles

2. A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. (PubMed)

A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. To systematically review the impact of Yasmin (drospirenone pill) compares with other standard treatments for symptoms of Polycystic Ovary Syndrome (PCOS).The relevant studies of the randomized controlled trials in women with PCOS treated with drospirenone were retrieved and the systematic evaluation was conducted.Eighteen articles were included. Compared

2016 European journal of obstetrics, gynecology, and reproductive biology

3. Yasmin

Yasmin Yasmin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Yasmin Yasmin Aka: Yasmin , Drosperinone , Yaz , Yasminelle , Ocella (...) , Zarah II. Indications III. Contraindications Hepatic insufficiency IV. Mechanism: Drosperinone Newer synthetic Antiandrogenic activity similar to Lowest Marginal benefit over other low androgen OCPs Antimineralcorticoid effect (Related to ) Only OCP with antimineralcorticoid activity Drospirenone 3 mg is equivalent to 25 mg V. Efficacy Similar to other s VI. Formulations Yaz (3/20 with 24 days and 4 days) Yasminelle (3/20 with 21 days and 7 days) Yasmin, Ocella or Zarah (3/30) VII. Drug Interactions

2018 FP Notebook

4. Pregnancy is more dangerous than the pill: A critical analysis of professional responses to the Yaz/Yasmin controversy. (PubMed)

Pregnancy is more dangerous than the pill: A critical analysis of professional responses to the Yaz/Yasmin controversy. The fourth and most recent generation of hormones used in oral contraceptives has stirred a significant amount of debate regarding the safety of these compounds. Drospirenone, a new type of synthetic hormone used in popular oral contraceptives Yaz and Yasmin, has been found by epidemiologists to increase the risk of blood clots when compared to the previous generations (...) of pills. North American regulatory bodies have investigated the health risks of drospirenone and concluded that the increased risks do not require pulling the new contraceptive technology off the market. Instead, the FDA and Health Canada along with several medical associations have actively managed the Yaz/Yasmin controversy through official statements and press releases between 2010 and 2014. This study provides an analysis of these documents and how risk information about drospirenone-containing

2016 Social Science & Medicine

5. What is the evidence for the use of Yasmin OCP,as opposed to Dianette ,and also what is the evidence for the use of metformin in Polycystic Ovary Syndrome in non Diabetic women ?.

What is the evidence for the use of Yasmin OCP,as opposed to Dianette ,and also what is the evidence for the use of metformin in Polycystic Ovary Syndrome in non Diabetic women ?. What is the evidence for the use of Yasmin OCP,as opposed to Dianette ,and also what is the evidence for the use of metformin in Polycystic Ovary Syndrome in non Diabetic women ?. - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY (...) for the use of Yasmin OCP,as opposed to Dianette ,and also what is the evidence for the use of metformin in Polycystic Ovary Syndrome in non Diabetic women ?. ATTRACT found no trials that compared Yasmin to Dianette in women with PCOS. However, there is a large amount of evidence on the use of metformin in PCOS. A 2008 meta-analysis of metformin use in PCOS (1) reports: “Seventeen RCTs were included in the review (n=1,639 women); sample size ranged from 18 to 626. Trials varied in methodological quality

2012 TRIP Answers

6. Yasmin

Yasmin Yasmin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Yasmin Yasmin Aka: Yasmin , Drosperinone , Yaz , Yasminelle , Ocella (...) , Zarah II. Indications III. Contraindications Hepatic insufficiency IV. Mechanism: Drosperinone Newer synthetic Antiandrogenic activity similar to Lowest Marginal benefit over other low androgen OCPs Antimineralcorticoid effect (Related to ) Only OCP with antimineralcorticoid activity Drospirenone 3 mg is equivalent to 25 mg V. Efficacy Similar to other s VI. Formulations Yaz (3/20 with 24 days and 4 days) Yasminelle (3/20 with 21 days and 7 days) Yasmin, Ocella or Zarah (3/30) VII. Drug Interactions

2015 FP Notebook

7. Comparison of Body Weight Change During Contraception With Belara and Yasmin

Comparison of Body Weight Change During Contraception With Belara and Yasmin Comparison of Body Weight Change During Contraception With Belara and Yasmin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Comparison of Body Weight Change During Contraception With Belara and Yasmin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01608698 Recruitment Status : Unknown Verified April 2015 by Mahidol University. Recruitment status was: Enrolling by invitation First Posted : May 31, 2012 Last Update Posted

2012 Clinical Trials

8. Yasmin: risk of venous thromboembolism higher than levonorgestrel-containing pills

Yasmin: risk of venous thromboembolism higher than levonorgestrel-containing pills Yasmin: risk of venous thromboembolism higher than levonorgestrel-containing pills - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Yasmin: risk of venous thromboembolism higher than levonorgestrel-containing pills Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs. Published 11 (...) , these studies have shown that women who use pills that contain desogestrel or gestodene have a slightly higher risk of developing VTE than do those who use levonorgestrel-containing pills. The excess risk of VTE is highest during the first year a woman ever starts or switches their COC. Yasmin contains drospirenone, a relatively new progestogen, and was first licensed in 2000. Evidence of the level of VTE risk associated with Yasmin has been accruing since then. The results of two early prospective cohort

2011 MHRA Drug Safety Update

9. Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate

Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination (...) of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01258660 Recruitment Status : Completed First Posted : December 13, 2010 Results First Posted : May 13, 2011 Last Update Posted : September 20, 2013

2010 Clinical Trials

10. Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) a

Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) a Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (...) (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet

2010 Clinical Trials

11. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. (PubMed)

Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and other positive effects of a combined oral contraceptive (COC) containing drospirenone (DRSP) [Yasmin] with those of a COC containing desogestrel (DSG) in healthy Chinese women. This was a randomized, open-label, controlled, multicentre

2010 Clinical drug investigation

12. What evidence is available comparing the difference in risk between Yasmin, Dianette and the third generation pill marvelon containing desogestrel?

What evidence is available comparing the difference in risk between Yasmin, Dianette and the third generation pill marvelon containing desogestrel? What evidence is available comparing the difference in risk between Yasmin, Dianette and the third generation pill marvelon containing desogestrel? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title (...) aim to deliver for every single search. As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What evidence is available comparing the difference in risk between Yasmin, Dianette

2009 TRIP Answers

13. For women using liver enzyme inducing drugs can a double dose of a combined oral contraceptive pill be used (Yasmin)?

For women using liver enzyme inducing drugs can a double dose of a combined oral contraceptive pill be used (Yasmin)? For women using liver enzyme inducing drugs can a double dose of a combined oral contraceptive pill be used (Yasmin)? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title (...) evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com For women using liver enzyme inducing drugs can a double dose of a combined oral contraceptive pill be used (Yasmin)? According to the Faculty of Sexual

2008 TRIP Answers

14. For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given?

For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere (...) clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? According to the Faculty of Sexual and Reproductive Healthcare: "If a woman

2008 TRIP Answers

15. For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given?

For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com For a woman switching from Dianette to a combined oral contraceptive (Yasmin), what advice should be given? We could find no robust guidance so we contacted the Faculty of Sexual and Reproductive

2008 TRIP Answers

16. Estradiol

of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) websites for up-to-date information. Summary Nomegestrol/ estradiol (Zoely) has similar contraceptive efficacy to drospirenone/ethinylestradiol (Yasmin) with similar numbers of days of unscheduled bleeding, fewer days of withdrawal bleeding and significantly more absence of withdrawal bleeding. Acne and weight gain were reported more frequently in women taking nomegestrol/ estradiol than in women taking

2018 Trip Latest and Greatest

17. The management of primary mediastinal B?cell lymphoma: Good Practice Paper

should be considered for female patients but commonly this is not feasible because of the mode of presentation (De Vos et al , ; Yasmin et al , ). Whilst the rate of infertility in young patients treated with R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) may be relatively low (Elis et al , ), the addition of extra chemotherapy agents may affect the rate of infertility or premature ovarian failure and therefore the risks of each individual therapeutic regimen should (...) . ( 2016 ) Phase III randomized study of R‐CHOP versus DA‐EPOCH‐R and molecular analysis of untreated diffuse large B‐cell lymphoma: CALGB/alliance 50303 . Blood , 128 , 469 – 469 . Yasmin, E. , Balachandren, N. , Davies, M.C. , Jones, G.L. , Lane, S. , Mathur, R. , Webber, L. & Anderson, R.A. ( 2018 ) Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline . Human Fertility , 21 , 3 – 26 . Zelenetz, A.D. , Gordon, L.I. , Wierda, W.G

2019 British Committee for Standards in Haematology

18. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights

for these and other contributors are provided in Annex 1 of this guideline. Special thanks are due to the external contributors who led the the Grading of Recommendations Assessment, Development and Evaluation (GRADE) systematic reviews – Caitlin Kennedy, Yasmin Ogale and Ping Teresa Yeh – and also to the guideline methodologist, Nandi Siegfried. Another external contributor to supporting evidence was Christopher Pell. We acknowledge the following external partners: Christine Galavotti (Bill & Melinda Gates

2019 World Health Organisation Guidelines

19. Hormonal Contraceptives

– 0.25 mg x7 Tri-cyclen® LO EE 25mcg Norgestimate 0.18mg x7 – 0.215mg x7 – 0.25 mg x7 4 th Generation Yasmin® Zamine™ Zarah™ EE 30mcg Drospirenone 3mg Yaz® Mya™ EE 20mcg Drospirenone 3mg (24 active pills, 4 placebo) Yaz® Plus EE 20mcg Drospirenone 3mg Levomefolate 0.45mg (folic acid supplement) (24 active pills, 4 placebo) *Progesterone only pill (Micronor 0.35mg) is also an option for nursing women. Some generics may not be in this list, but would still be eligible for pharmacist prescription. Table

2018 medSask

20. Diabetes drug aids fertility in women with polycystic ovaries

consider a woman’s weight before recommending treatment. Citation and Funding Morley LC, Tang T, Yasmin E, et al. . Cochrane Database Syst Rev. 2017;11:CD003053. No external funding was received. Bibliography NICE. . London: National Institute for Health and Care Excellence; 2013. Why was this study needed? Polycystic ovarian syndrome is a hormonal disorder which affects between 5 and 15% of women of reproductive age. Ovulation is often suppressed, making it harder for women to get pregnant. Women (...) success of metformin and clomifene for women of different weights reinforces the suggestion in NICE guidelines that clinicians consider a woman’s weight before recommending treatment. Citation and Funding Morley LC, Tang T, Yasmin E, et al. . Cochrane Database Syst Rev. 2017;11:CD003053. No external funding was received. Bibliography NICE. . London: National Institute for Health and Care Excellence; 2013. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women

2019 NIHR Dissemination Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>